In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.
Upon successful completion of this educational activity, participants should be better able to:
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH
Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC
Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
